Remdesivir
- Generic Name
- Remdesivir
- Brand Names
- Veklury
- Drug Type
- Small Molecule
- Chemical Formula
- C27H35N6O8P
- CAS Number
- 1809249-37-3
- Unique Ingredient Identifier
- 3QKI37EEHE
- Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp)...
- Indication
Remdesivir is indicated for the treatment of adult and pediatric patients 28 days of age and older and weighing at least 3 kg for coronavirus disease 2019 (COVID-19) infection requiring hospitalization. It is also indicated for the treatment of non-hospitalized patients with mild-to-moderate COVID-19, who are at high risk for progression to severe COVID-19, ...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- King Edward Medical University
- Target Recruit Count
- 66
- Registration Number
- NCT04871633
- Locations
- 🇵🇰
Mayo Hospital, Lahore, Punjab, Pakistan
SARS-CoV-2 Human Challenge Characterisation Study
- Conditions
- Interventions
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 36
- Registration Number
- NCT04865237
- Locations
- 🇬🇧
Royal Free Foundation Hospital, London, United Kingdom
🇬🇧hVIVO Services Ltd, QMB Bioenterprise building, London, United Kingdom
Remdesivir Efficacy In Management Of COVID-19 Patients
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 77
- Registration Number
- NCT04853901
- Locations
- 🇪🇬
Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt
Safety of Remdesivir Treatment in COVID-19 Patients Requiring Hemodialysis
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Semmelweis University
- Target Recruit Count
- 45
- Registration Number
- NCT04854837
- Locations
- 🇭🇺
Semmelweis University - Department of Internal Medicine and Oncology, Budapest, Hungary
Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- NEAT ID Foundation
- Target Recruit Count
- 451
- Registration Number
- NCT04847622
- Locations
- 🇫🇷
CHU de Nantes, Nantes, France
🇫🇷Hospital Lariboisiere, Paris, France
🇫🇷Hopital Saint-Louis, Paris, France
Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)
- Conditions
- Interventions
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- ASST Fatebenefratelli Sacco
- Target Recruit Count
- 4000
- Registration Number
- NCT04832880
- Locations
- 🇮🇹
Ospedale di Ferrara, Ferrara, Italy
🇮🇹ASST Santi Paolo e Carlo, Milan, Italy
🇮🇹ASST Fatebenefratelli-Sacco, Milan, Italy
Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
- Conditions
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 205
- Registration Number
- NCT04784559
- Locations
- 🇧🇷
Hospital Felicio Rocho, Belo Horizonte, MG, Brazil
🇲🇽Universidad Autonoma de Nuevo Leon - Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, NL, Mexico
🇷🇴Institutul National De Boli Infectioase "Prof. Dr. Matei Bals", Bucharest, Romania
Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- October 6 University
- Target Recruit Count
- 150
- Registration Number
- NCT04779047
- Locations
- 🇪🇬
Beni-suef University, Banī Suwayf, Egypt
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
- Conditions
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 249
- Registration Number
- NCT04745351
- Locations
- 🇺🇸
Holy Cross Hospital, Silver Spring, Maryland, United States
🇺🇸MedStar Health Research Institute, Washington, District of Columbia, United States
🇺🇸George Washington Medical Faculty Associates, Washington, District of Columbia, United States
Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients
- Conditions
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Ahmed Essam
- Target Recruit Count
- 90
- Registration Number
- NCT04738045
- Locations
- 🇪🇬
Beni-suef University, Banī Suwayf, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.